ACC 2014 Report: Benefits of treating heart attack patients with a cheap drug
The 6-month follow-up data from the METOCARD-CNIC trial are published in the Journal of the American College of Cardiology.
The 6-month follow-up data from the METOCARD-CNIC trial are published in the Journal of the American College of Cardiology.
Use of the drug aleglitazar, which has shown the ability to lower glucose levels and have favorable effects on cholesterol, did not reduce the risk of cardiovascular death,… read more.
Report from the ACC Annual Scientific Meeting, 29 – 31 March 2014 in Washington. Angiotensin-converting-enzyme (ACE) inhibitors are associated with reduced mortality and cardiovascular events in patients… read more.